Lumipulse® G SARS-CoV-2 N-IgG Controls
For in vitro diagnostic (IVD) use as quality controls, to monitor the precision and accuracy of the Lumipulse G SARS-CoV-2 N-IgG assay on the automated LUMIPULSE G System. The assay using this control is performed to quantitatively measure IgG antibodies to SARS-CoV-2 nucleocapsid (N) protein in human serum or plasma and is intended to be used in the assessment of the immune response to the SARS-CoV-2 N protein.
Product number 232354
-
Documentation
Browse regulatory documents for this product
Create a (free!) eServices account and start browsing all regulatory documentation right away.
Get access to this section and more
Create a free eServices account now and instantly access multiple digital resources:
- Regulatory product documentation
- Selected scientific posters
- Product leaflets
- How-to videos and more…
-
Insights
Lumipulse G SARS-CoV-2 Ag was the first high-sensitive nucleocapsid protein antigen assay launched on a fully automated chemiluminescent platform.
...
May 27, 2021
Large-scale and fully automated COVID-19 antigen testing for travelers in German airports
Since November 2020 Fujirebio Europe and CENTOGENE have partnered to leverage LUMIPULSE® G technology for large-scale COVID-19 antigen testing in...
May 11, 2021
During this webinar Dr. Francesco Bonella (MD - Center for Interstitial & Rare Lung Disease, Department of Pulmonology, Ruhrlandklinik University...
Oct 19, 2020
-
Related products
-
Product inquiry
